Company news

Share this article:
MANUFACTURER NEWS
Astellas Pharma Technologies is offering early retirement to 200 workers at its Norman, OK, plant. The cuts anticipate the patent expiration Flomax.
 
Merck KGaA, the German manufacturer of Erbitux cancer treatment, has announced a partnership with Belgian biotech Ablynx NV to develop tumor and immune disorder treatments. 
 
 
AGENCY NEWS
Concentric Pharma Advertising has won an AOR assignment on Surfaxin, an investigational respiratory distress syndrome (RDS) treatment manufactured by Discovery Labs.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies